91 related articles for article (PubMed ID: 9017009)
1. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Fujiwara Y; Takahashi T; Yamakido M; Ohune T; Tsuya T; Egorin MJ
J Natl Cancer Inst; 1997 Feb; 89(3):260-2. PubMed ID: 9017009
[No Abstract] [Full Text] [Related]
2. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Minami H; Ando Y; Saka H; Shimokata K
J Natl Cancer Inst; 1997 Jul; 89(13):968-70. PubMed ID: 9214677
[No Abstract] [Full Text] [Related]
3. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Sridhara R
J Natl Cancer Inst; 1997 Oct; 89(20):1546-7. PubMed ID: 9337355
[No Abstract] [Full Text] [Related]
4. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
Bénézet S; Guimbaud R; Chatelut E; Chevreau C; Bugat R; Canal P
Ann Oncol; 1997 Jun; 8(6):607-9. PubMed ID: 9261532
[TBL] [Abstract][Full Text] [Related]
5. Reference values of serum and urine creatinine, and of creatinine clearance by a new enzymatic method.
Sugita O; Uchiyama K; Yamada T; Sato T; Okada M; Takeuchi K
Ann Clin Biochem; 1992 Sep; 29 ( Pt 5)():523-8. PubMed ID: 1444164
[TBL] [Abstract][Full Text] [Related]
6. Measurement of creatine in urine by creatinase, sarcosine oxidase, and peroxidase reevaluated.
Beyer C; Alting IH; Backer ET
Clin Chem; 1993 Aug; 39(8):1743-4. PubMed ID: 8394792
[No Abstract] [Full Text] [Related]
7. A fluorophotometric determination of serum creatinine and creatine using a creatinineamidohydrolase-creatineamidinohydrolase-sarcosine oxidase-peroxidase system and diacetyldichlorofluorescin.
Kinoshita T; Hiraga Y
Chem Pharm Bull (Tokyo); 1980 Dec; 28(12):3501-6. PubMed ID: 7226292
[No Abstract] [Full Text] [Related]
8. A new enzymatic determination of serum creatine.
Suzuki M; Yoshida M
Clin Chim Acta; 1984 Jul; 140(3):289-94. PubMed ID: 6467615
[No Abstract] [Full Text] [Related]
9. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
11. [Prediction of carboplatin clearance from morphological and biological patient characteristics].
Chatelut E; Dezeuze A; Lavit M; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R; Canal P
Bull Cancer; 1995 Nov; 82(11):946-53. PubMed ID: 8535021
[TBL] [Abstract][Full Text] [Related]
12. Immobilized enzyme electrode for creatinine determination in serum.
Nguyen VK; Wolff CM; Seris JL; Schwing JP
Anal Chem; 1991 Mar; 63(6):611-4. PubMed ID: 2031562
[TBL] [Abstract][Full Text] [Related]
13. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.
Chatelut E; Canal P; Brunner V; Chevreau C; Pujol A; Boneu A; Roché H; Houin G; Bugat R
J Natl Cancer Inst; 1995 Apr; 87(8):573-80. PubMed ID: 7752255
[TBL] [Abstract][Full Text] [Related]
14. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
15. Creatinine assay by the fuller's earth procedure or by enzymatic determination is adequate for urine but not plasma of mice.
Meyer MH; Smith S; Meyer RA
Comp Biochem Physiol B; 1993 Nov; 106(3):685-9. PubMed ID: 8281763
[TBL] [Abstract][Full Text] [Related]
16. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
[TBL] [Abstract][Full Text] [Related]
17. A new enzymatic method to determine creatine.
Yasuhara M; Fujita S; Arisue K; Kohda K; Hayashi C
Clin Chim Acta; 1982 Jul; 122(2):181-8. PubMed ID: 7105406
[TBL] [Abstract][Full Text] [Related]
18. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.
Thomas F; Séronie-Vivien S; Gladieff L; Dalenc F; Durrand V; Malard L; Lafont T; Poublanc M; Bugat R; Chatelut E
Clin Pharmacokinet; 2005; 44(12):1305-16. PubMed ID: 16372828
[TBL] [Abstract][Full Text] [Related]
19. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
20. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
